399 related articles for article (PubMed ID: 16750166)
1. Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142.
Chalupny NJ; Rein-Weston A; Dosch S; Cosman D
Biochem Biophys Res Commun; 2006 Jul; 346(1):175-81. PubMed ID: 16750166
[TBL] [Abstract][Full Text] [Related]
2. Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein.
Welte SA; Sinzger C; Lutz SZ; Singh-Jasuja H; Sampaio KL; Eknigk U; Rammensee HG; Steinle A
Eur J Immunol; 2003 Jan; 33(1):194-203. PubMed ID: 12594848
[TBL] [Abstract][Full Text] [Related]
3. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity.
Dunn C; Chalupny NJ; Sutherland CL; Dosch S; Sivakumar PV; Johnson DC; Cosman D
J Exp Med; 2003 Jun; 197(11):1427-39. PubMed ID: 12782710
[TBL] [Abstract][Full Text] [Related]
4. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
[TBL] [Abstract][Full Text] [Related]
5. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
Song H; Kim J; Cosman D; Choi I
Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
[TBL] [Abstract][Full Text] [Related]
6. Differential NKG2D binding to highly related human NKG2D ligands ULBP2 and RAET1G is determined by a single amino acid in the alpha2 domain.
Wittenbrink M; Spreu J; Steinle A
Eur J Immunol; 2009 Jun; 39(6):1642-51. PubMed ID: 19424970
[TBL] [Abstract][Full Text] [Related]
7. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
[TBL] [Abstract][Full Text] [Related]
8. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein.
Rölle A; Mousavi-Jazi M; Eriksson M; Odeberg J; Söderberg-Nauclér C; Cosman D; Kärre K; Cerboni C
J Immunol; 2003 Jul; 171(2):902-8. PubMed ID: 12847260
[TBL] [Abstract][Full Text] [Related]
9. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
[TBL] [Abstract][Full Text] [Related]
10. Proteolytic release of soluble UL16-binding protein 2 from tumor cells.
Waldhauer I; Steinle A
Cancer Res; 2006 Mar; 66(5):2520-6. PubMed ID: 16510567
[TBL] [Abstract][Full Text] [Related]
11. The inhibitory effects of synthetic short peptides, mimicking MICA and targeting at NKG2D receptors, on function of NK cells.
Zhang B; Wei H; Zheng X; Zhang J; Sun R; Tian Z
Peptides; 2005 Mar; 26(3):405-12. PubMed ID: 15652646
[TBL] [Abstract][Full Text] [Related]
12. The herpesviral Fc receptor fcr-1 down-regulates the NKG2D ligands MULT-1 and H60.
Lenac T; Budt M; Arapovic J; Hasan M; Zimmermann A; Simic H; Krmpotic A; Messerle M; Ruzsics Z; Koszinowski UH; Hengel H; Jonjic S
J Exp Med; 2006 Aug; 203(8):1843-50. PubMed ID: 16831899
[TBL] [Abstract][Full Text] [Related]
13. MCMV glycoprotein gp40 confers virus resistance to CD8+ T cells and NK cells in vivo.
Krmpotić A; Busch DH; Bubić I; Gebhardt F; Hengel H; Hasan M; Scalzo AA; Koszinowski UH; Jonjić S
Nat Immunol; 2002 Jun; 3(6):529-35. PubMed ID: 12021778
[TBL] [Abstract][Full Text] [Related]
14. Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein.
Wu J; Chalupny NJ; Manley TJ; Riddell SR; Cosman D; Spies T
J Immunol; 2003 Apr; 170(8):4196-200. PubMed ID: 12682252
[TBL] [Abstract][Full Text] [Related]
15. MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
Friese MA; Platten M; Lutz SZ; Naumann U; Aulwurm S; Bischof F; Bühring HJ; Dichgans J; Rammensee HG; Steinle A; Weller M
Cancer Res; 2003 Dec; 63(24):8996-9006. PubMed ID: 14695218
[TBL] [Abstract][Full Text] [Related]
16. Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide.
Kim JY; Bae JH; Lee SH; Lee EY; Chung BS; Kim SH; Kang CD
J Immunother; 2008 Jun; 31(5):475-86. PubMed ID: 18463537
[TBL] [Abstract][Full Text] [Related]
17. NKG2D and Related Immunoreceptors.
Strong RK; McFarland BJ
Adv Protein Chem; 2004; 68():281-312. PubMed ID: 15500864
[TBL] [Abstract][Full Text] [Related]
18. Cell surface organization of stress-inducible proteins ULBP and MICA that stimulate human NK cells and T cells via NKG2D.
Eleme K; Taner SB; Onfelt B; Collinson LM; McCann FE; Chalupny NJ; Cosman D; Hopkins C; Magee AI; Davis DM
J Exp Med; 2004 Apr; 199(7):1005-10. PubMed ID: 15051759
[TBL] [Abstract][Full Text] [Related]
19. Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients.
Salih HR; Goehlsdorf D; Steinle A
Hum Immunol; 2006 Mar; 67(3):188-95. PubMed ID: 16698441
[TBL] [Abstract][Full Text] [Related]
20. Expression and function of NKG2D in CD4+ T cells specific for human cytomegalovirus.
Sáez-Borderías A; Gumá M; Angulo A; Bellosillo B; Pende D; López-Botet M
Eur J Immunol; 2006 Dec; 36(12):3198-206. PubMed ID: 17109473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
